Dr. huijuan Wang is an oncologist in Zhengzhou, China. She received her medical degree from Zhengzhou University and has been in practice for less than 10 year.

Myung-Ju Ahn is Professor of Hemato-Oncology at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul. She is a member of numerous research associations and societies, including the ISLAC, AACR, and ASCO and is currently Chief of the Executive Committee and Chairperson of Lung Cancer Disease Committee of the KCSG. She is the current president of the KSMO and was chairperson of the multidisciplinary Immuno-oncology Study Group (2017–2018). She is a board member for the KCA, KSMO and KALC, and is on the editorial board of Journal of Thoracic Oncology.

Prof Ahn received her medical and doctoral degrees from Hanyang University College of Medicine, Seoul and completed her residency training at Hanyang University Hospital. She has held numerous research fellowships, including a postdoctoral research fellowship at the Memorial Sloan-Kettering Cancer Center, New York, and has authored over 250 cancer research publications. Her research interests include the development of predictive and prognostic markers for personalised lung cancer therapy. She has recently focused on early clinical trials for the development of drug discovery and reposition of targeted drugs and the development of a NSCLC genome atlas. She is a member of multiple associations and societies dedicated to cancer research such as ASCO, IASLC, and the Korean Cancer Study Group, where she is also Chief of the executive committee and chairperson of Lung Cancer Disease Committee. She was a president of the Korean Society of Medical Oncology. Her accolades for her dedication to cancer research include Best Researcher Award, Korean Medical Women Association (2003); Best Researcher Award from Korean Society of Medical Oncology (2015); Boryoung Scientific Award from Korean Cancer Research Foundation (2018), Wunsch Medical Award from Korean Academy of Medical Science (2020), and Highly Cited Researcher, Clavirate analytics (2019,2020).

Keunchil Park is Professor of the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Professor Park had served as Chair of the Scientific Committee of the Korean Cancer Association(KCA), Chair of the Lung Cancer Committee of the Korean Cancer Study Group (KCSG) and also served as Chairman of the Board of Directors, Korean Association for Clinical Oncology (KACO).
He is an active member of the International Association for the Study of Lung Cancer (IASLC) and has been involved in many IASLC activities since 1996, including Scientific Secretary of the 12th World Conference on Lung Cancer (WCLC; Sept, 2007), and President of the 4th Asia Pacific Lung Cancer Conference (Dec, 2010). He also served the IASLC as the Board of Directors since 2009 to 2013. More recently Prof. Park served as Co-President with Prof. Hisao Asamura of the 18th WCLC, Oct 15-18, 2017, Yokohama, Japan. He received the Merit Award of IASLC in 2016.
Prof. Park is also actively involved in a variety of international activities of ASCO (American Society of Clinical Oncology) as a member of the International Education Steering Group (IESG) and the Asia Pacific Regional Council (Chair in June 2019- June 2021). He also served as Chair of the Korea Actionable Genome Consortium (KAGC) 2015-2018 and the Scientific Co-Chair for ESMO-Asia 2017 (Singapore, 16 -19, Nov. 2017).
Prof. Park is a member of the International Cancer Genome Consortium (ICGC) Scientific Steering Committee since 2013 and served as Organizing Chairman of the 13th ICGC workshop, June 12-14, 2017 in Seoul, Korea. He was nominated as Steering Committee member of ICGC-ARGO (Accelerating Research in Genomic Oncology) which is the second phase of ICGC and launched in May, 2018 and recently appointed as Member of the Management Committee. He recently appointed as President of the Korean Cancer Association(KCA).
He is an Associate Editor for the Journal of Thoracic Oncology (JTO) and Therapeutic Advances in Medical oncology, and Editorial Advisory Board member of Cancer.
His main interests include translational researches as well as early clinical trials for lung cancer. Prof. Park has led several global early clinical trials of the targeted agents and immune check point inhibitors and pioneered in developing precision oncology for lung cancer. He also conducted many pre-clinical development programs as well as genomic researches. Prof. Park has several book chapters and authored more than 400 peer-reviewed publications in national and international journals.

Dr Jiyun Lee is an Associate Clinical Professor at the Department of Medicine, Sungkyunkwan University School of Medicine, Seoul. She completed her M.D. at Daegu Catholic University College of Medicine and completed her residency training and fellowship at Samsung Medical Center. Her research interests include the molecular profiling of lung cancer and the development of personalized treatments and predictive biomarkers.